Trial Profile
A Multicenter, Open-label, Phase 1 Pilot Study of ACP-196 in Combination With ACP-319 in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 19 Jul 2023
Price :
$35
*
At a glance
- Drugs Acalabrutinib (Primary) ; ACP 319 (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Adverse reactions
- Sponsors Acerta Pharma
- 14 Jul 2023 Planned End Date changed from 31 Dec 2025 to 31 May 2026.
- 23 Mar 2021 According to ClinicalTrials.gov, trial focus has been changed from AR and PK to AR.
- 30 Jan 2019 Planned primary completion date changed from 1 Sep 2018 to 1 Jul 2020.